These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 10521263

  • 1. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Lashuel HA, Wurth C, Woo L, Kelly JW.
    Biochemistry; 1999 Oct 12; 38(41):13560-73. PubMed ID: 10521263
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colón W.
    Biochemistry; 1995 Oct 17; 34(41):13527-36. PubMed ID: 7577941
    [Abstract] [Full Text] [Related]

  • 4. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z, Colón W, Kelly JW.
    Biochemistry; 1996 May 21; 35(20):6470-82. PubMed ID: 8639594
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
    Jiang X, Smith CS, Petrassi HM, Hammarström P, White JT, Sacchettini JC, Kelly JW.
    Biochemistry; 2001 Sep 25; 40(38):11442-52. PubMed ID: 11560492
    [Abstract] [Full Text] [Related]

  • 7. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
    Cardoso I, Goldsbury CS, Müller SA, Olivieri V, Wirtz S, Damas AM, Aebi U, Saraiva MJ.
    J Mol Biol; 2002 Apr 12; 317(5):683-95. PubMed ID: 11955017
    [Abstract] [Full Text] [Related]

  • 8. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution.
    Quintas A, Saraiva MJ, Brito RM.
    FEBS Lett; 1997 Dec 01; 418(3):297-300. PubMed ID: 9428731
    [Abstract] [Full Text] [Related]

  • 9. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
    Rodrigues JR, Simões CJ, Silva CG, Brito RM.
    Protein Sci; 2010 Feb 01; 19(2):202-19. PubMed ID: 19937650
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
    Colon W, Kelly JW.
    Biochemistry; 1992 Sep 15; 31(36):8654-60. PubMed ID: 1390650
    [Abstract] [Full Text] [Related]

  • 13. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.
    Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, Miroy GJ, Peterson SA.
    Adv Protein Chem; 1997 Sep 15; 50():161-81. PubMed ID: 9338081
    [Abstract] [Full Text] [Related]

  • 14. Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.
    Ferrão-Gonzales AD, Palmieri L, Valory M, Silva JL, Lashuel H, Kelly JW, Foguel D.
    J Mol Biol; 2003 May 09; 328(4):963-74. PubMed ID: 12729768
    [Abstract] [Full Text] [Related]

  • 15. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.
    Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM.
    J Biol Chem; 2001 Jul 20; 276(29):27207-13. PubMed ID: 11306576
    [Abstract] [Full Text] [Related]

  • 16. Initial conformational changes of human transthyretin under partially denaturing conditions.
    Yang M, Lei M, Bruschweiler R, Huo S.
    Biophys J; 2005 Jul 20; 89(1):433-43. PubMed ID: 15821170
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.
    Sörgjerd K, Ghafouri B, Jonsson BH, Kelly JW, Blond SY, Hammarström P.
    J Mol Biol; 2006 Feb 17; 356(2):469-82. PubMed ID: 16376939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.